

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 November 2020 (19.11.2020)



(10) International Publication Number
WO 2020/231837 A1

(51) International Patent Classification:

A61K 31/56 (2006.01) A61P 25/08 (2006.01)

A61K 31/568 (2006.01) A61P 25/24 (2006.01)

(21) International Application Number:

PCT/US2020/032172

(22) International Filing Date:

08 May 2020 (08.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/846,576 10 May 2019 (10.05.2019) US

63/018,815 01 May 2020 (01.05.2020) US

(71) Applicant: **BRII BIOSCIENCES, INC.** [US/US]; WeWork One City Ctr., Unit 05-130, 110 Corcoran St., Durham, North Carolina 27701 (US).

(72) Inventors: **STRICKLEY, Robert G.**; c/o Brii Biosciences, Inc., WeWork One City Ctr., Unit 05-130, 110 Corcoran St., Durham, North Carolina 27701 (US). **XU, Lianhong**; c/o Brii Biosciences, Inc., WeWork One City Ctr., Unit 05-130, 110 Corcoran St., Durham, North Carolina 27701 (US). **HONG, Zhi**; c/o Brii Biosciences, Inc., WeWork One City Ctr., Unit 05-130, 110 Corcoran St., Durham, North Carolina 27701 (US).

(74) Agent: **YU, Xiaozhen** et al.; Cooley LLP, 1299 Pennsylvania Ave, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMPOSITION CONTAINING BREXANOLONE, GANAXOLONE, OR ZURANOLONE, AND USE THEREOF




FIG. 2A

(57) Abstract: Disclosed herein is a pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid that is a positive modulator of γ aminobutyric acid type A (GABA_A) receptors. Also disclosed are methods of treating diseases using the pharmaceutical composition and processes of producing the pharmaceutical composition.

WO 2020/231837 A1